GENE ONLINE|News &
Opinion
Blog

2022-05-09|

Illumina to Pay BGI $333M Following Infringement Case

by Fujie Tham
Share To

A federal jury in Delaware, US found several Illumina DNA sequencing platforms violated 2 of the Chinese BGI Group Complete Genomics Inc’s patents. An Illumina spokesperson said the company disagrees with the decision and plans to appeal.

The jury also established that 3 of the Illumina rights Complete Genomics was accused of the breach were invalid, and should not have been issued in the first place. Illumina’s stock (ILMN.O) was down around 15% following the news.

Related article: APCM 2022: Precision Medicine Is Opening Up a New Prospect of Cancer Therapy

 

The Debated 2-Channel Technology

 

The Californian BGI subsidiary, Complete Genomics filed the suit in mid-2019, claiming that San Diego-based Illumina’s 2-channel sequencing system infringed patents for the technology which determines each DNA nucleotide from two signals. Rather than using a separate dye for each base, the 2-channel system simplifies nucleotide detection by using two fluorescent dyes and two images to determine all four nucleotides. Both companies argue their exclusivity to above technology, with Illumina claiming that it invented its 2-channel technology before the BGI patents, and that BGI was unable to make 2-channel chemistry work until it copied Illumina’s technology.

BGI attacked Illumina’s NovaSeq 6000, the NextSeq 500/550/550x, 1000/2000 Series, and the MiniSeq. It also targeted Illumina’s library preparation kits and sequencing kits compatible with multiple platforms, saying that when used in combination with some systems, will violate BGI’s rights.

Illumina’s spokesperson said the company plans to appeal and that the verdict should not affect its ability to supply its customers and the attorney for BGI said the company was pleased with the award, which the judge could multiply based on the willful infringement finding. Recently, this March, Illumina obtained a ban on some BGI sequencers and won $8M for BGI’s violation of its patents. The companies are in a global legal campaign over their respective patents, with court cases in countries including Germany, Switzerland, the UK and Turkey.

Both BGI and Illumina are set to benefit from the global genetic sequencing market, which is expected to reach $35,503M by 2030, growing at 18% annually in regard to rapid growth and demands for genome-analysis technology on genetic diseases.

©www.geneonline.com All rights reserved. Collaborate with us: [email protected]
Related Post
Illumina Stepping It Up in Gene Sequencing Innovation with Global Launch of New Tech—MiSeq i100 Series in Taipei
2024-10-16
Illumina and NTU Hospital Sign Collaboration Agreement to Launch Large-Scale Whole Genome Sequencing Project
2024-10-16
Illumina’s IVD Biomarker Test Becomes the First FDA-approved Pan-cancer Companion Diagnostics Kit
2024-09-11
LATEST
The Golden Age of Medicine: Advancements in Novel Modalities and Therapeutic Areas
2024-11-01
Strengthening Biotech Ties: Highlights from the BioConnect Forum and Future Collaboration between Taiwan and Australia
2024-10-31
AusBiotech 2024 Opening Ceremony: From Local to Global – Shaping the Future of Life Sciences and Biotech in Australia
2024-10-30
AMS BioteQ Showcases Game-Changing Innovations at Medical Japan 2024
2024-10-29
AusBiotech 2024 to Highlight Global Areas of Interest, Current Trends, and Research Directives in Australia’s Diverse Biotech Industry
2024-10-25
BPIPO and DCB Collaborate with NVIDIA to Host AI Forum, Focusing on Cross-Domain Integration for Precision Health
2024-10-25
CDMO Samsung Bio Secures Record $1.24 Billion Biopharma Manufacturing Contract, Raising Total 2024 Deal Value to Over $3.3 Billion
2024-10-23
EVENT
2024-11-04
BIO-Europe 2024
Stockholm, Sweden
Scroll to Top